InfuSystem (NYSE:INFU) Lowered to Buy Rating by StockNews.com

StockNews.com cut shares of InfuSystem (NYSE:INFU) from a strong-buy rating to a buy rating in a research report report published on Thursday morning.

InfuSystem Stock Performance

InfuSystem stock opened at $6.25 on Thursday. The company’s 50-day moving average price is $7.96 and its 200-day moving average price is $7.60. InfuSystem has a twelve month low of $5.74 and a twelve month high of $9.97. The company has a quick ratio of 1.59, a current ratio of 1.98 and a debt-to-equity ratio of 0.50. The company has a market cap of $132.90 million, a PE ratio of 104.18 and a beta of 1.75.

Institutional Trading of InfuSystem

A number of large investors have recently made changes to their positions in INFU. GSA Capital Partners LLP increased its holdings in shares of InfuSystem by 23.9% in the 3rd quarter. GSA Capital Partners LLP now owns 65,680 shares of the company’s stock worth $440,000 after buying an additional 12,657 shares during the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock worth $223,000 after buying an additional 7,295 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in InfuSystem during the 3rd quarter valued at about $87,000. BNP Paribas Financial Markets grew its holdings in InfuSystem by 66.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock valued at $27,000 after purchasing an additional 1,626 shares during the last quarter. Finally, State Street Corp grew its holdings in InfuSystem by 1.1% during the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock valued at $1,789,000 after purchasing an additional 3,019 shares during the last quarter. 71.13% of the stock is currently owned by institutional investors.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.